2 ms·
> from one or two clinical trials warrants From one or two?? Cognitive outcomes of anti-amyloid-β monoclonal antibodies in patients with Alzheimer's disease:
by nabla9 4y ago
> from one or two clinical trials warrants
From one or two??
Cognitive outcomes of anti-amyloid-β monoclonal antibodies in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.057778 https://alz-journals.onlinelibrary.wiley.com/doi/full/10.100...
Had Enough, Eh? Come Back and Take What's Coming to You!
https://www.science.org/content/blog-post/had-enough-eh https://www.science.org/content/blog-post/had-enough-eh
- subroutine 4y agoOk, there's more than I knew about. "We found 12 eligible studies in 443 identified records, involving 6736 patients, mean age 71.4 ± 2. We found a small benefit in cognitive outcomes in patients treated with Aβ-mAbs." So there's a small benefit to using antibody treatment. To me suggests that Abeta is a good target, but antibodies are not a sufficient Rx. Have you seen a brain at BRAAK stage 4-6?